A University of Birmingham spinout. The Native Antigen Company (NAC) specialises in the R&D and scale up manufacturing of highly pure viral and bacterial native antigens. NAC's antigens are used primarily by pharmaceutical and IVD manufacturers in vaccine research and serology. As well as offering antigens from a rapidly expanding portfolio, NAC undertakes bespoke product development and partnering.
- Investment status Realised
- Invested 2010
- Category Health & Life Sciences